Search

Displaying results 2881 - 2890 of 10000 in total
  1. Drug

    Carboxin

    go.drugbank.com/drugs/DB04657
    ApprovedWithdrawn

    A systemic agricultural fungicide and seed treatment agent.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065] … Achondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits

  3. Drug

    Aclidinium

    go.drugbank.com/drugs/DB08897
    Approved

    Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). … It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.

  4. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. … Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension.

    Products: MOXONIDIN AL 0.2MG FILMTAB, MOXONIDIN AL 0.3MG FILMTAB
  5. Drug

    Diphenylguanidine

    go.drugbank.com/drugs/DB14191
    Approved

    Diphenylguanidine is a complexing agent used in the detection of metals and organic bases and used as an accelerator in the vulcanization of rubber. It is found in some rubber products. … It is also a dermatological sensitizer and allergen. Sensitivity to diphenylguanidine may be identified with a clinical patch test.

  6. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.

  7. Drug

    Medrysone

    go.drugbank.com/drugs/DB00253
    Approved

    Medrysone is a corticosteroid used in ophthalmology.

  8. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    [A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. … It presents selectivity against the mutant forms of EGFR compared to the wild-type.

  9. Drug

    PRO 2000

    go.drugbank.com/drugs/DB05385
    Investigational

    It is being studied for the prevention of HIV infection and other sexually transmitted diseases. … PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    Dehydrocholic acid is a synthetic bile acid that was prepared from the oxidation of cholic acid with chromic acid [A33022]. It has been used for stimulation of biliary lipid secretion. … The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.